Here are five updates on GI companies from the past week:
GI & Endoscopy
A study, published in The American Journal of Gastroenterology, examined what patients value from inflammatory bowel disease biologic medicines.
A study, published in The American Journal of Gastroenterology, examined the efficacy and safety of linaclotide for patients with chronic idiopathic constipation.
A study, published in The American Journal of Gastroenterology, examined the impact depression has on inflammatory bowel disease patients.
Medscape released its "2018 Physician Lifestyle & Happiness Report," compiling physicians' opinions on a wide array of lifestyle choices.
Advertisement
Donnie Smith, MD, is a gastroenterologist at Tuscaloosa-based GI Associates of West Alabama.
On the heels of announcing its preliminary fiscal year 2017 results, Exact Sciences announced plans to ramp up sales and marketing efforts to push the company's flagship product, Cologuard, Xconomy Wisconsin reports.
Motus GI Holdings, a medical device company, filed a $29 million initial public offering with the Securities Exchange Commission Jan. 5, Renaissance Capital reports.
CMS released the ASC Quality Reporting data for 2018 payment year, covering the average number of procedures performed at ASCs per state in select specialties.
Christopher Brown, MD, is a gastroenterologist at Atlanta Gastroenterology Associates.